ShRNA en tratamiento in vivo: perspectiva terapéutica en la enfermedad de Alzheimer

ShRNA en tratamiento in vivo: perspectiva terapéutica en la enfermedad de Alzheimer

Las enfermedades neurodegenerativas son un problema creciente en la población senil, con más de 20 millones de personas afectadas por la enfermedad de Alzheimer (EA) esporádica en el mundo y más de 5.000 portadores de EA familiar sólo en el departamento de Antioquia.

Bibliographic Details
Main Authors:	Kenneth Kosik, Álvaro Barrera Ocampo, Gloria Patricia Cardona Gómez
Format:	Article
Language:	Spanish
Published:	Universidad de Antioquia 2005-03-01
Series:	Iatreia
Subjects:	Alzheimer, BACE 1 RNA interferente
Online Access:	http://www.iatreia.udea.edu.co/index.php/iatreia/article/view/1120

Similar Items

Lobotomía de genes: terapia génica, RNA interferente y enfermedad de Alzheimer
by: Ryan Boudreau, et al.
Published: (2005-03-01)

Expression analysis of beta-secretase 1 (BACE1) enzyme in peripheral blood of patients with Alzheimer\'s disease
by: Alireza Vakilian, et al.
Published: (2019-06-01)

Synaptic abnormalities in a Drosophila model of Alzheimer’s disease
by: Siddhita D. Mhatre, et al.
Published: (2014-03-01)

Multifunctional magnetite nanoparticles to enable delivery of siRNA for the potential treatment of Alzheimer’s
by: Natalia Lopez-Barbosa, et al.
Published: (2020-01-01)

BACE1 RNAi restores the composition of phosphatidylethanolamine-derivates related to memory improvement in aged 3xTg-AD mice
by: Javier Gustavo Villamil, et al.
Published: (2016-11-01)

Interferentes eritrocitários e ambientais na anemia falciforme
by: Naoum Paulo C.
Published: (2000-01-01)

BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
by: Miguel A. Maia, et al.
Published: (2019-03-01)

The microrna-mediated regulation of proteins implicated in the pathogenesis of Alzheimer's Disease
by: Chopra, Nipun
Published: (2017)

Characterization of Diagnostic Tools and Potential Treatments for Alzheimer’s Disease : PET ligands and BACE1 inhibitors
by: Jeppsson, Fredrik
Published: (2016)

Use of Peptides for the Management of Alzheimer’s Disease: Diagnosis and Inhibition
by: Mohammad H. Baig, et al.
Published: (2018-02-01)

BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer’s disease
by: Chami Linda, et al.
Published: (2012-10-01)

Decreased expression of GGA3 Protein in Alzheimer's disease frontal cortex and increased co-distribution of BACE with the amyloid precursor protein
by: Claudia Santosa, et al.
Published: (2011-07-01)

Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide
by: Dey, J., et al.
Published: (2022)

Comparative Evaluation of the Antioxidant and Anti-Alzheimer’s Disease Potential of Coumestrol and Puerarol Isolated from Pueraria lobata Using Molecular Modeling Studies
by: Prashamsa Koirala, et al.
Published: (2018-03-01)

Reduction BACE1 expression via suppressing NF-κB mediated signaling by Tamibarotene in a mouse model of Alzheimer’s disease
by: Aimin Qiao, et al.
Published: (2021-06-01)

Development and Structural Modification of BACE1 Inhibitors
by: Ting Gu, et al.
Published: (2016-12-01)

BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer’s Disease Pathology
by: Gerald Koelsch
Published: (2017-10-01)

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease
by: Michael F. Egan, et al.
Published: (2019-08-01)

The Role of microRNAs in Alzheimer’s Disease and Their Therapeutic Potentials
by: Munvar Miya Shaik, et al.
Published: (2018-03-01)

Therapeutic Effects of Transplanted Exosomes Containing miR-29b to a Rat Model of Alzheimer’s Disease
by: Yavar Jahangard, et al.
Published: (2020-06-01)

MicroRNAs in Alzheimer's disease
by: Charlotte Delay, et al.
Published: (2012-05-01)

Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid-β production in human neuron-like cells
by: Sutinen Elina M, et al.
Published: (2012-08-01)

A Tale of Two Drug Targets: The Evolutionary History of BACE1 and BACE2
by: Christopher eSouthan, et al.
Published: (2013-12-01)

The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
by: Ulf Neumann, et al.
Published: (2018-11-01)

Application of Ferulic Acid for Alzheimer’s Disease: Combination of Text Mining and Experimental Validation
by: Guilin Meng, et al.
Published: (2018-05-01)

Alzheimer’s associated amyloid and tau deposition co-localizes with a homeostatic myelin repair pathway in two mouse models of post-stroke mixed dementia
by: Thuy-Vi V. Nguyen, et al.
Published: (2018-09-01)

CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
by: François Mouton-Liger, et al.
Published: (2020-07-01)

Loss of Bace1 in mice does not alter the severity of caerulein induced pancreatitis
by: Heindl, Mario, et al.
Published: (2015)

Delivery of Quantum Dot-siRNA Nanoplexes in SK-N-SH Cells for BACE1 Gene Silencing and Intracellular Imaging
by: Shengliang Li, et al.
Published: (2012-01-01)

Design, Synthesis and Biological Evaluation of 2,4-Disubstituted Pyrimidine Derivatives: Multifunctional Candidates as Potential Treatment Options for Alzheimer’s Disease
by: Mohamed, Tarek
Published: (2011)

Design, Synthesis and Biological Evaluation of 2,4-Disubstituted Pyrimidine Derivatives: Multifunctional Candidates as Potential Treatment Options for Alzheimer’s Disease
by: Mohamed, Tarek
Published: (2011)

Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors
by: Michela Guglielmotto, et al.
Published: (2010-02-01)

The Perspective of Dysregulated LncRNAs in Alzheimer's Disease: A Systematic Scoping Review
by: Mohammad Reza Asadi, et al.
Published: (2021-09-01)

Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer’s Disease: A Pilot Study
by: Carola G. Schipke, et al.
Published: (2018-08-01)

Role of BACE1 in Alzheimer’s synaptic function
by: Brati Das, et al.
Published: (2017-08-01)

Glycosaminoglycans from <i>Litopenaeus vannamei</i> Inhibit the Alzheimer’s Disease β Secretase, BACE1
by: Courtney J. Mycroft-West, et al.
Published: (2021-04-01)

Roles of eIF2α kinases in the pathogenesis of Alzheimer’s disease
by: Masuo eOhno, et al.
Published: (2014-04-01)

The Decrease of Uch-L1 Activity Is a Common Mechanism Responsible for Aβ 42 Accumulation in Alzheimer’s and Vascular Disease
by: Michela Guglielmotto, et al.
Published: (2017-09-01)

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study
by: Gerald Novak, et al.
Published: (2020-05-01)

Triptolide treatment reduces Alzheimer’s disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD
by: Qi Wang, et al.
Published: (2014-12-01)